Recently, we showed the important role of ERRγ in upregulating NIS function in anaplastic thyroid cancer (ATCs) using the selective inverse agonist of ERRγ, GSK5182 (a 4-hydroxy tamoxifen analog) [20]. This evidence concerns the gene SLC5A5 and thyroid gland undifferentiated (anaplastic) carcinoma.